Elevance Health (NYSE:ELV) Price Target Raised to $424.00

Elevance Health (NYSE:ELV) had its target price upped by Sanford C. Bernstein from $384.00 to $424.00 in a report issued on Friday,MarketScreener reports. The firm currently has an “outperform” rating on the stock. Sanford C. Bernstein’s price target points to a potential upside of 22.68% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the company. Guggenheim restated a “buy” rating and set a $399.00 price target on shares of Elevance Health in a research note on Friday. Jefferies Financial Group cut their price objective on Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a research report on Monday. Weiss Ratings downgraded Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, February 2nd. JPMorgan Chase & Co. boosted their target price on shares of Elevance Health from $394.00 to $397.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Finally, Royal Bank Of Canada cut shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price target on the stock. in a research note on Tuesday, February 3rd. Eleven research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $384.65.

Elevance Health Stock Down 0.2%

Shares of Elevance Health stock traded down $0.67 on Friday, reaching $345.62. 159,449 shares of the company were exchanged, compared to its average volume of 1,858,392. Elevance Health has a 1-year low of $273.71 and a 1-year high of $427.54. The company has a market cap of $75.92 billion, a P/E ratio of 14.67, a price-to-earnings-growth ratio of 1.83 and a beta of 0.49. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.54. The stock’s 50 day moving average price is $309.00 and its 200-day moving average price is $331.66.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. The firm had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same period in the prior year, the company posted $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities analysts forecast that Elevance Health will post 25.5 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Physician Wealth Advisors Inc. boosted its position in shares of Elevance Health by 331.6% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after buying an additional 63 shares in the last quarter. Rossby Financial LCC boosted its position in shares of Elevance Health by 110.0% in the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after buying an additional 44 shares in the last quarter. Activest Wealth Management boosted its position in shares of Elevance Health by 66.7% in the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after buying an additional 34 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new stake in shares of Elevance Health in the 4th quarter worth about $31,000. Finally, J.Safra Asset Management Corp purchased a new stake in shares of Elevance Health in the 4th quarter worth about $32,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Key Headlines Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q1 results and guidance lift sentiment — ELV reported better-than-expected Q1 EPS and raised its 2026 adjusted EPS outlook (targets 12% EPS growth in 2027), signaling stronger profitability and upward earnings momentum. Elevance raises 2026 adjusted EPS outlook
• Positive Sentiment: Management cites medical-cost controls and AI-driven operating discipline as drivers of margin expansion and a higher annual profit forecast — supports sustainable margin improvement. Health insurer Elevance raises annual profit forecast
• Positive Sentiment: Investment income helped EPS — rising net investment income materially boosted Q1 results, offsetting some membership pressure. ELV Beats Q1 on rising net investment income
• Positive Sentiment: Analyst support: Evercore raised its price target to $360, adding buy-side validation for the beat-and-raise story. Evercore raises price target on Elevance
• Positive Sentiment: Shareholder return: Board declared a quarterly dividend (supports income-oriented investors and reduces downside risk).
• Neutral Sentiment: Analyst stance mixed — Robert W. Baird raised its target to $331 but moved to a “neutral” rating, reflecting more cautious near-term expectations despite higher valuation work. Baird updates target and rating
• Neutral Sentiment: Operational caveat: Management noted membership declines; the topline impact is being offset by investment income and cost controls — watch membership trends for sustainability. Valuation and mixed Q1 draw attention
• Negative Sentiment: Legal risk: A law firm (Kirby McInerney LLP) has launched an investor investigation into potential securities-law claims involving Elevance and senior management — introduces regulatory/legal overhang and potential litigation risk. Investor alert: Kirby McInerney investigates Elevance

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.